Biopharmaceutical innovation and oncology therapeutics by Zymeworks (ZYME)
Zymeworks stock edges lower with short-term pressure despite event participation
Zymeworks will participate in the Jefferies Global Healthcare Conference in New York this week.Management is scheduled to join a fireside chat on June 3 at 8:45 a.m. ET. The session will cover the ...
Zymeworks schedules April investor conference presentations
Zymeworks management will participate in the Needham 25th Annual Virtual Healthcare Conference in April. The company is set to present to investors and hold virtual one-on-one meetings, with a ...
Zymeworks advances cancer research with new ADC program data at AACR Annual Meeting
Zymeworks is intensifying its engagement with the life sciences community by presenting both clinical and preclinical data from its antibody-drug conjugate (ADC) programs at this year’s AACR ...
Antibody drug discovery takes center stage at ESMO, Zymeworks outlines
Zymeworks announced the upcoming presentations by two of its senior researchers at the ESMO Targeted Anticancer Therapies Congress in Paris from March 16 to 19. Nina E. Weisser, Senior Director ...
Zymeworks secures Canadian approval for HER2 cancer therapy
Zymeworks has announced that Health Canada has approved its HER2-targeted therapy for the treatment of adults with previously treated, unresectable, or metastatic HER2-positive biliary tract ...
Zymeworks earns recognition from UBC as top co-op employer
Zymeworks, a prominent player in the biotechnology industry, has been recognized by the University of British Columbia (UBC) with the Co-op Employer Recognition Award. This accolade is given to ...
Zymeworks accelerates innovation with combination therapies
Zymeworks, a leader in biotechnology, is making strides in oncology with its novel approach to combination therapies. Presenting at the Biotech Showcase, Adam Schayowitz, Acting Chief Development ...
Zymeworks outlines long-term strategy shift leveraging positive Phase 3 data
Biotech firm Zymeworks has announced a fundamental shift in its long-term corporate strategy. The company aims to position itself for a more predictable and value-generating future. This move ...
Zymeworks reveals Q3 2025 financial results with corporate update
Zymeworks has disclosed its financial results for the third quarter of 2025, along with a corporate update. The pharmaceutical company, known for its focus on innovative therapeutics, shared ...
